Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors Preclinical data of DT-7012 position this Treg depleting anti-CCR8 antibody as a highly differentiated candidate for clinical development Preclinical findings demonstrate high potential of the PAR2 biased negative allosteric modulator (NAM) […]
Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its PAR2 biased negative allosteric modulator program Posters present the potential of GPCRs to modulate the tumor microenvironment and enhance anti-tumor immunity Strasbourg, France – Montreal, […]
Domain’s leadership will highlight advancements in its key programs in immuno-oncology and inflammation Key presentations on its first-in-class biased antagonist of PAR2 and best-in-class Treg-depleting anti-CCR8 antibody candidates Strasbourg, France – Montreal, Canada – Boston, United States, February 27, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for […]
